Actinium Cash Ratio from 2010 to 2024

ATNM Stock  USD 1.21  0.13  9.70%   
Actinium Pharmaceuticals Cash Ratio yearly trend continues to be very stable with very little volatility. Cash Ratio is likely to grow to 9.48 this year. During the period from 2010 to 2024, Actinium Pharmaceuticals Cash Ratio quarterly data regression pattern had sample variance of  21.00 and median of  3.73. View All Fundamentals
 
Cash Ratio  
First Reported
2010-12-31
Previous Quarter
9.02719567
Current Value
9.48
Quarterly Volatility
4.58220762
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Actinium Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Actinium Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Selling General Administrative of 14 M or Other Operating Expenses of 54.6 M, as well as many indicators such as Price To Sales Ratio of 1.8 K, Dividend Yield of 0.0 or PTB Ratio of 3.9. Actinium financial statements analysis is a perfect complement when working with Actinium Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Actinium Pharmaceuticals Correlation against competitors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.

Latest Actinium Pharmaceuticals' Cash Ratio Growth Pattern

Below is the plot of the Cash Ratio of Actinium Pharmaceuticals over the last few years. It is Actinium Pharmaceuticals' Cash Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Actinium Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Cash Ratio10 Years Trend
Slightly volatile
   Cash Ratio   
       Timeline  

Actinium Cash Ratio Regression Statistics

Arithmetic Mean4.94
Geometric Mean1.93
Coefficient Of Variation92.80
Mean Deviation3.92
Median3.73
Standard Deviation4.58
Sample Variance21.00
Range13.3276
R-Value0.82
Mean Square Error7.39
R-Squared0.67
Significance0.0002
Slope0.84
Total Sum of Squares293.95

Actinium Cash Ratio History

2024 9.48
2023 9.03
2022 10.25
2021 11.38
2020 13.33
2019 1.73
2018 2.26

About Actinium Pharmaceuticals Financial Statements

Actinium Pharmaceuticals investors utilize fundamental indicators, such as Cash Ratio, to predict how Actinium Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Ratio 9.03  9.48 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports:
Check out the analysis of Actinium Pharmaceuticals Correlation against competitors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.39)
Revenue Per Share
0.003
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.31)
Return On Equity
(0.88)
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.